



August 6, 2021

Company Takara Bio Inc. (1st Section TSE, code: 4974) Headquarters Nojihigashi 7-4-38, Kusatsu, Shiga, Japan

Representative Koichi Nakao, President

Contact Takuya Kakemi, Executive Officer,

President of Corporate Management Division

Telephone (+81)77-565-6970

Website https://www.takara-bio.co.jp/

[Updated] " Consolidated Financial Statements for the First Quarter Ended June 30, 2021 FY2022 (April 1, 2021 – June 30, 2021) [UNAUDITED]"

We announced that there were items that should be corrected in part of the descriptions in the "Consolidated Financial Statements for the First Quarter Ended June 30, 2021 FY2022 (April 1, 2021 – June 30, 2021) [UNAUDITED]" disclosed on August 3, 2021. Corrected areas are underlined.

Notes

1. Reason for Correction

After the disclosure on August 3, 2021, it has been corrected because some items that should be corrected are discovered in the descriptions.

2. Content of the correction

Summary of "Consolidated Financial Statements for the First Quarter Ended June 30, 2021 FY2022 (April 1, 2021 – June 30, 2021) [UNAUDITED]"

[Before revision]

1. Results for the three months ended June 30, 2021 (Apr. 1, 2021 – Jun. 30, 2021)

(1) Consolidated operating results

(Percentages indicate changes from the same period of the previous fiscal year.)

	Three months ended Jun. 30, 2021		Three months ended Jun. 30, 2020	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	15,272	220.1	6,938	(19.8)
Operating profit	8,504	-	693	(69.2)
Ordinary profit	8,579	-	745	(66.1)
Net income (loss) attributable to owners of parent	6,025	-	404	(74.6)
Net income per share (in yen)	50.04		3.36	
Fully diluted net income per share (in yen)	-		-	
(Note) Comprehensive income	8,210	(-%)	(48)	(-%)

[After Correction]

	Three months ended Jun. 30, 2021		Three months ended Jun. 30, 2020	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	15,272	<u>120.1</u>	6,938	(19.8)
Operating profit	8,504	-	693	(69.2)
Ordinary profit	8,579	-	745	(66.1)
Net income (loss) attributable to owners of parent	6,025	-	404	(74.6)
Net income per share (in yen)	50.04		3.36	
Fully diluted net income per share (in yen)	-		-	
(Note) Comprehensive income	8,210	(-%)	(48)	(-%)

End